Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

pembrolizumab 28Cisplatin 24Oxaliplatin 22Irinotecan 22Fluorouracil 22Capecitabine 20Leucovorin 17Paclitaxel 16Cyclophosphamide 14Trastuzumab 12Nivolumab 11Carboplatin 11Gemcitabine 10Bevacizumab 10Docetaxel 9fludarabine 8aldesleukin 8S 1 (combination) 8Ramucirumab 7130-nm albumin-bound paclitaxel 7atezolizumab 6Albumin-Bound Paclitaxel 6Taxes 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Biopsy 5veliparib 4tislelizumab 4spartalizumab 4dehydroftorafur 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Stomach Neoplasms × GC1118 × Clear all
NCT02352571 2016-07-06

Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer

GC Biopharma Corp

Phase 1 Unknown
72 enrolled
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡